Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

women’s health strategy

- PMLiVE

FDA grants priority review for traditional approval of Biogen and Eisai’s Alzheimer’s drug

Leqembi was granted accelerated approval in the US earlier this year

Biogen Idec building

Safety-related change to label for Biogen’s Alzheimer’s drug Aduhelm approved by FDA

Larger areas of bleeding on the brain have been reported in some patients taking the drug

- PMLiVE

Alzheimer’s Research UK welcomes government’s pledge to tackle dementia crisis

The commitments form part of a new UK-wide strategy to alleviate pressures on the health system

- PMLiVE

Alzheimer’s Society urges UK government to deliver on dementia plan

The strategy, announced in May last year, includes doubling dementia research funding

- PMLiVE

Eli Lilly’s Alzheimer’s drug denied FDA accelerated approval

The FDA said there was not enough trial data from patients who were treated for at least a year

Biogen Idec building

Biogen and Eisai’s Alzheimer’s drug receives FDA accelerated approval

An application has also been submitted for US approval under the traditional pathway

- PMLiVE

BioXcel Therapeutics doses first patient in phase 3 Alzheimer’s-associated agitation trial

Around 100 million agitation episodes are reported in the US each year in Alzheimer’s patients

- PMLiVE

Eisai and Washington University to develop neurodegenerative disease therapies

Alzheimer’s will be a central focus for the new drug discovery collaboration

- PMLiVE

New study links hearing restorative devices to slower rate of memory decline

The use of hearing aids and cochlear implants reduced long-term cognitive decline by 19%

- PMLiVE

Lilly’s donanemab shows promise in early symptomatic Alzheimer’s comparator study

Brain amyloid clearance was achieved in 37.9% of patients treated with the investigational antibody

Biogen Idec building

Biogen and Eisai’s Alzheimer’s drug shown to slow memory decline in confirmatory study

The findings have been described as a ‘major step forward’ for dementia research

- PMLiVE

Alzheimer’s Research UK welcomes government’s recommitment to dementia mission

One million people are predicted to be living with dementia by 2025, increasing to 1.6 million by 2040

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links